Biogen (BIIB)

Executive Summary

Biogen is a leading biotechnology company focused on advancing therapies for neurological and neurodegenerative diseases. Despite headwinds from the contested launch of Aduhelm, Biogen has refocused its pipeline, leveraging its strong multiple sclerosis (MS) franchise (Tecfidera, Tysabri, Plegridy) and advancing Alzheimer's disease (AD) portfolio with lecanemab (Leqembi), co-developed with Eisai. The company also explores gene therapies and antisense oligonucleotides for rare diseases. Key upcoming catalysts include the potential conversion of lecanemab to full FDA approval, which could expand patient access and reimbursement, and key readouts from early-stage AD candidates targeting tau and other pathways. With a market cap of ~$27B and a robust R&D engine, Biogen is positioned to regain growth through pipeline progression and label expansions, though it faces patent cliffs and competitive pressures in MS. The conviction score reflects a balanced view of its established base and promising but risky pipeline.

Upcoming Catalysts (preview)

• Q3 2026FDA Full Approval Decision for Lecanemab (Leqembi) in Early Alzheimer's Disease85% success
• Q4 2026Phase 2/3 Data Readout for BIIB080 (MAPT Antisense Oligonucleotide) in Alzheimer's Disease55% success
• Q2 2026FDA Decision on Tofersen (Qalsody) Confirmatory Data for SOD1-ALS75% success